The University of Wisconsin-Madison has partnered with 18 other sites across North America in a National Heart, Lung, and Blood Institute-funded lung transplant consortium. The goal of the consortium is to enroll up to 2600 lung transplant patients in various observational and biobanking research studies over the next four years. With an increasing number of lung transplants performed each year, the results of these studies have the potential to improve the outcomes for many lung transplant patients in the future.
This is an accordion element with a series of buttons that open and close related content panels.
Lung Transplant Recipient Exosome Phenotypes and the Risk of Primary Graft Dysfunction and Acute Lung Allograft Dysfunction
Lung Transplant Recipient Exosome Phenotypes and the Risk of Primary Graft Dysfunction and Acute Lung Allograft Dysfunction is an NIH-funded, multi-center observational study. The primary objective is to identify a biomarker to predict primary graft dysfunction (PGD) and acute lung allograft disfunction (ALAD) in lung transplant patients. Participants in this study provide serum samples prior to transplant, during the perioperative period, and at various timepoints in the year following lung transplantation.
The main site for this study is the University of Washington-Seattle, with additional sites at the University of Michigan and the University of Wisconsin-Madison. Funding for this project is anticipated to run through August of 2027.
PROMISE: A Prospective Multicenter Study to Evaluate Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
The University of Wisconsin-Madison is one of 19 sites participating in a prospective observational study focusing on patient reported outcomes up to four years post-lung transplantation. This study also includes a biobanking aspect. The lead sites for this study are Duke University and the University of Pennsylvania.